International Journal in Physical and Applied Sciences
Volume 11 Issue 12, Dec 2024 ISSN: 2394-5710 Impact Factor: 8.202
Journal Homepage: http://ijmr.net.in, Email: irjmss@gmail.com
Double-Blind Peer Reviewed Refereed Open Access International Journal

The Role of Albumin-Globulin Ratio in Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease

Shrish Sharma
Research Scholar, Department of Biochemistry, Index Medical College, Malwanchal University
Prof. Dr Savita Rathore
Professor, Department of Biochemistry, Index Medical College, Malwanchal University

Abstract

Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD) are closely interconnected metabolic disorders, with NAFLD being one of the most common hepatic complications in diabetic patients. NAFLD encompasses a spectrum of conditions ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. The progression of NAFLD in T2DM patients is often accelerated due to insulin resistance, chronic inflammation, and metabolic dysregulation.

The albumin-globulin ratio (AGR), a simple and cost-effective laboratory biomarker, reflects both hepatic synthetic function (via albumin levels) and systemic inflammation (via globulin levels). Emerging evidence suggests that a low AGR is associated with increased severity of NAFLD, advanced fibrosis, and cardiovascular risk in diabetic individuals. As chronic inflammation and liver dysfunction progress, the decline in AGR may serve as an early warning signal for disease advancement.

Recent studies have demonstrated significant correlations between AGR and various NAFLD-related complications, including hepatic fibrosis, cardiovascular disease, and metabolic syndrome. AGR has also been proposed as a potential predictor of long-term outcomes, helping clinicians in early risk stratification and treatment planning. However, despite its promising role, further large-scale studies are needed to validate AGR as a reliable biomarker for routine clinical use in NAFLD management.

Keywords - Albumin-Globulin Ratio (AGR), Type 2 Diabetes Mellitus (T2DM), Non-Alcoholic Fatty Liver Disease (NAFLD), Inflammation, Liver Fibrosis

1. Introduction

What are Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD)?

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, hyperglycemia, and progressive pancreatic β-cell dysfunction. It is associated with multiple complications, including cardiovascular diseases, nephropathy, neuropathy, and non-alcoholic fatty liver disease (NAFLD). NAFLD is a hepatic manifestation of metabolic syndrome and is one of the most prevalent liver diseases worldwide, affecting approximately 25% of the global population (Younossi et al., 2019). The prevalence of NAFLD is even higher in T2DM patients, ranging from

50% to 70%, due to the shared pathophysiology of insulin resistance and metabolic dysfunction (Tilg et al., 2021).

NAFLD encompasses a spectrum of liver abnormalities, ranging from simple hepatic steatosis (fat accumulation in hepatocytes) to non-alcoholic steatohepatitis (NASH), which is characterized by inflammation, hepatocellular injury, and fibrosis. If left unchecked, NAFLD can progress to cirrhosis, liver failure, or hepatocellular carcinoma (HCC), significantly increasing morbidity and mortality rates (Byrne et al., 2018).

Why is Early Detection of NAFLD Important in Diabetic Patients?

The coexistence of NAFLD and T2DM accelerates liver disease progression and significantly increases the risk of cardiovascular disease, chronic kidney disease, and liver-related mortality (Mantovani et al., 2020). Studies have shown that diabetic patients with NAFLD are more likely to develop advanced fibrosis compared to non-diabetic individuals, making early detection crucial for preventing severe complications (Eslam et al., 2020).Despite its clinical importance, NAFLD is often underdiagnosed due to its asymptomatic nature in early stages. Liver biopsy remains the gold standard for diagnosing NAFLD and assessing fibrosis, but it is invasive, costly, and impractical for routine screening (Cusi, 2021). Therefore, there is a growing need for non-invasive, cost-effective biomarkers that can aid in the early identification and risk stratification of NAFLD in diabetic patients.

What is Albumin-Globulin Ratio (AGR), and Why is it Being Studied?

The albumin-globulin ratio (AGR) is a readily available laboratory marker derived from serum albumin and globulin levels. It reflects both hepatic synthetic function (via albumin levels) and systemic inflammation (via globulin levels). A decrease in AGR is often associated with chronic inflammatory states, liver dysfunction, and fibrosis, making it a potential indicator of disease severity in NAFLD patients (Huang et al., 2022).

- **Albumin** is a protein synthesized by the liver, playing a crucial role in maintaining oncotic pressure, transporting hormones, and exerting anti-inflammatory and antioxidant effects. Low albumin levels often indicate impaired liver function and chronic disease (Kim et al., 2021).
- **Globulin** consists of immunoglobulins and other inflammatory proteins that increase in response to systemic inflammation, autoimmunity, or liver dysfunction (Liu et al., 2021).
- **AGR**, calculated as albumin divided by globulin, serves as an indirect marker of systemic inflammation and hepatic function. A lower AGR has been linked to advanced fibrosis, cardiovascular risk, and overall poor prognosis in various liver diseases (Wang et al., 2022).

Given that both inflammation and liver dysfunction play key roles in NAFLD progression, AGR has gained attention as a potential non-invasive biomarker for evaluating disease severity in diabetic patients.

Aim of This Paper

This review aims to explore the role of AGR in understanding NAFLD progression in patients with T2DM. Specifically, it will examine:

1. The relationship between AGR and NAFLD severity.
2. The potential of AGR in predicting liver fibrosis and cardiovascular complications.
3. The clinical utility of AGR in risk stratification and treatment monitoring.
4. The limitations of AGR and the need for further research.

By summarizing recent findings and discussing AGR's potential applications, this paper seeks to contribute to the ongoing efforts in improving early diagnosis and management of NAFLD in diabetic patients.

2. What is Albumin-Globulin Ratio (AGR)?

The albumin-globulin ratio (AGR) is a simple yet informative blood test parameter that reflects the balance between two major protein groups in the blood: albumin and globulin. This ratio is increasingly being studied as a potential marker for various health conditions, including liver diseases such as non-alcoholic fatty liver disease (NAFLD), particularly in diabetic patients.

Albumin and Globulin: An Overview

1. Albumin

Albumin is the most abundant plasma protein, primarily synthesized by the liver. It plays several essential roles, including:

- **Maintaining oncotic pressure** – Albumin helps regulate fluid balance between blood vessels and surrounding tissues, preventing edema.
- **Transporting molecules** – It binds and transports hormones, fatty acids, bilirubin, and medications.
- **Exhibiting antioxidant and anti-inflammatory properties** – Albumin can scavenge free radicals and modulate inflammatory responses.

In healthy individuals, albumin levels remain relatively stable, but chronic liver diseases, malnutrition, kidney dysfunction, and systemic inflammation can lead to reduced albumin production (Kim et al., 2021).

2. Globulin

Globulin refers to a group of proteins that include immunoglobulins (antibodies), complement proteins, clotting factors, and transport proteins. These proteins are primarily involved in:

- **Immune response regulation** – Immunoglobulins play a key role in defending against infections.
- **Inflammation control** – Certain globulin fractions, such as C-reactive protein (CRP) and fibrinogen, are elevated during chronic inflammation.
- **Transport and enzymatic functions** – Some globulins transport iron (transferrin) and copper (ceruloplasmin) in the bloodstream.

Globulin levels may increase due to chronic inflammatory conditions, infections, autoimmune diseases, or liver dysfunction, which disrupts normal protein metabolism (Liu et al., 2021).

Why Does the Albumin-Globulin Ratio Matter in Liver Health?

The albumin-globulin ratio (AGR) is calculated as:

$$AGR = \frac{\text{Serum Albumin}}{\text{Serum Globulin}}$$

Since albumin is a marker of liver synthetic function and globulin is associated with systemic inflammation, the AGR provides a valuable indicator of both hepatic function and inflammatory status. A **low AGR** may signal:

1. **Liver Dysfunction:**
    - Reduced albumin production due to hepatocellular damage or fibrosis (Huang et al., 2022).
    - Increased globulin levels due to impaired protein metabolism in liver disease (Wang et al., 2022).
2. **Chronic Inflammation:**
    - NAFLD and non-alcoholic steatohepatitis (NASH) are associated with systemic inflammation, which can elevate globulin levels, further reducing AGR (Xu et al., 2021).
    - Inflammatory markers such as C-reactive protein (CRP) and interleukin-6 (IL-6) often correlate with lower AGR values in patients with metabolic diseases (Zhao et al., 2021).
3. **Fibrosis and Cirrhosis Progression:**
    - Studies suggest that AGR decreases as liver fibrosis advances, making it a potential biomarker for identifying high-risk patients (Kim et al., 2021).

Thus, a lower AGR is generally associated with more severe liver disease, making it a useful, non-invasive indicator for clinicians evaluating NAFLD in diabetic patients.

AGR as an Easy-to-Measure Blood Marker

One of the biggest advantages of AGR is its accessibility and ease of measurement:

- It is **calculated from routine blood tests**, making it a cost-effective and widely available biomarker.
- Unlike liver biopsy or specialized imaging techniques like transient elastography, AGR can be measured through **standard blood panels**, reducing patient discomfort and healthcare costs (Liu et al., 2021).

- When used alongside other non-invasive fibrosis markers, such as the FIB-4 index or NAFLD fibrosis score (NFS), AGR may enhance diagnostic accuracy in liver disease evaluation (Huang et al., 2022).

Given these benefits, AGR holds potential as a simple, cost-effective tool for early risk stratification and disease monitoring in diabetic patients with NAFLD. However, further large-scale studies are needed to establish standardized cutoff values and validate its clinical utility in predicting disease progression.

3. AGR and NAFLD in Diabetic Patients

How NAFLD Develops in People with Diabetes

Non-Alcoholic Fatty Liver Disease (NAFLD) is strongly associated with Type 2 Diabetes Mellitus (T2DM), largely due to shared metabolic risk factors such as insulin resistance, obesity, and dyslipidemia. NAFLD in diabetic patients progresses more rapidly and carries a higher risk of complications, including liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) (Eslam et al., 2020).

The pathogenesis of NAFLD in T2DM involves several interconnected mechanisms:

1. **Insulin Resistance and Hepatic Steatosis**
    - Insulin resistance, a hallmark of T2DM, leads to increased free fatty acid (FFA) flux from adipose tissue to the liver, resulting in excessive hepatic fat accumulation (Tilg et al., 2021).
    - Impaired insulin signaling also reduces hepatic lipoprotein export, exacerbating fat deposition in the liver (Cusi, 2021).
2. **Chronic Inflammation and Fibrosis Progression**
    - Low-grade systemic inflammation in T2DM, driven by increased cytokine levels (TNF-α, IL-6), contributes to hepatocyte injury and fibrogenesis (Mantovani et al., 2020).
    - Elevated levels of globulin (immunoglobulins and inflammatory proteins) indicate systemic inflammation, which is reflected in a lower albumin-globulin ratio (AGR) (Huang et al., 2022).
3. **Oxidative Stress and Mitochondrial Dysfunction**
    - Oxidative stress and mitochondrial dysfunction play a key role in transitioning from simple steatosis to non-alcoholic steatohepatitis (NASH), increasing the risk of fibrosis and cirrhosis (Liu et al., 2021).
    - As hepatic inflammation worsens, albumin synthesis decreases while globulin levels rise, further lowering AGR values.

The interplay between these factors accelerates NAFLD progression in diabetic patients, making early detection crucial for preventing severe liver-related complications.

Studies Showing the Relationship Between AGR and NAFLD

Recent research has demonstrated a significant association between AGR and NAFLD severity, particularly in diabetic populations:

- **Low AGR is correlated with advanced fibrosis:**
  - A study by Huang et al. (2022) found that diabetic NAFLD patients with lower AGR values had a higher prevalence of advanced fibrosis (F3-F4 stages) compared to those with normal AGR levels.
  - Patients with AGR <1.2 were more likely to have significant liver stiffness measured by transient elastography.
- **AGR as a predictor of systemic inflammation in NAFLD:**
  - Liu et al. (2021) reported that patients with lower AGR exhibited increased levels of inflammatory markers such as CRP, IL-6, and ferritin, indicating a stronger inflammatory response in NAFLD progression.
  - This study suggested that AGR might serve as an indirect marker of both hepatic and extrahepatic complications of NAFLD.
- **AGR and cardiovascular risk in diabetic NAFLD patients:**
  - A cohort study by Wang et al. (2022) highlighted that patients with low AGR (<1.1) had a significantly higher incidence of major cardiovascular events, suggesting a dual role of AGR in predicting both liver and cardiovascular disease risks in NAFLD patients with T2DM.

These findings suggest that AGR is not only reflective of liver disease severity but also provides insight into broader metabolic and cardiovascular risks in diabetic patients.

Can AGR Be Used to Detect NAFLD Early?

Given its accessibility and ease of measurement, AGR holds promise as a **non-invasive, early detection tool** for NAFLD in diabetic patients. Some potential applications include:

1. **Screening Tool for High-Risk Patients:**
   - AGR can help identify diabetic patients at risk of developing NAFLD before significant liver damage occurs.
   - In combination with other non-invasive markers (e.g., FIB-4, NAFLD Fibrosis Score), AGR may improve the accuracy of early NAFLD detection (Xu et al., 2021).
2. **Monitoring Disease Progression and Treatment Response:**
   - Longitudinal studies suggest that declining AGR values correlate with worsening liver function, making it a useful biomarker for disease monitoring (Kim et al., 2021).
   - AGR can also be used to assess the effectiveness of lifestyle and pharmacological interventions in NAFLD management.
3. **Risk Stratification for Liver Fibrosis:**
   - As fibrosis is the strongest predictor of liver-related mortality in NAFLD, AGR could aid in stratifying patients based on their likelihood of developing advanced fibrosis (Zhao et al., 2021).
   - Patients with persistently low AGR values may benefit from closer surveillance and earlier intervention.

Limitations and Future Research

- AGR values can be influenced by other factors such as kidney disease, nutritional status, and infections, which may limit its specificity for NAFLD diagnosis.
- Large-scale, prospective studies are needed to establish standardized cutoff values and validate its predictive utility in clinical settings.
- Further research should explore the integration of AGR with other emerging biomarkers (e.g., gut microbiome markers, genetic predisposition scores) to improve diagnostic accuracy.

The growing body of evidence supports AGR as a **useful, non-invasive biomarker** for assessing NAFLD severity in diabetic patients. A lower AGR is consistently associated with greater liver fibrosis, systemic inflammation, and increased cardiovascular risk. Given its cost-effectiveness and availability, AGR could play an important role in early detection, risk stratification, and disease monitoring in diabetic patients with NAFLD. However, more research is needed to refine its clinical applications and establish standardized diagnostic thresholds.

4. AGR vs. Other Liver Tests

The albumin-globulin ratio (AGR) has emerged as a promising biomarker for assessing liver health, particularly in patients with Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD). However, AGR is just one of several markers used in clinical practice. To understand its diagnostic value, it is essential to compare it with other common liver tests, including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and fibrosis scores such as the Fibrosis-4 (FIB-4) index and NAFLD Fibrosis Score (NFS).

Comparison of AGR with Common Liver Tests

Test	Primary Function	Advantages	Limitations
Alanine Aminotransferase (ALT)	Marker of hepatocyte injury	Widely available, inexpensive	Can be normal in advanced NAFLD; lacks specificity for fibrosis (Cusi, 2021)
Aspartate Aminotransferase (AST)	Marker of liver inflammation and fibrosis	Useful in AST/ALT ratio to predict fibrosis	Less sensitive in early NAFLD; elevated in non-liver conditions (Tilg et al., 2021)
FIB-4 Index	Non-invasive fibrosis marker combining AST, ALT, age, and platelet count	Good for identifying advanced fibrosis	Less accurate in younger patients and early-stage NAFLD (Huang et al., 2022)
NAFLD Fibrosis Score (NFS)	Predicts liver fibrosis based on age, BMI, AST/ALT, platelets, and albumin	Effective for distinguishing mild from severe fibrosis	Complex calculation; less reliable in intermediate fibrosis stages (Wang et al., 2022)

Test	Primary Function	Advantages	Limitations
AGR (Albumin-Globulin Ratio)	Reflects liver function and inflammation	Simple, cost-effective, and widely available	Affected by non-liver factors (infections, kidney disease, malnutrition) (Liu et al., 2021)

Benefits of Using AGR in NAFLD Diagnosis

1. **Easily Accessible and Cost-Effective**
   - AGR is calculated from routine blood tests (serum albumin and globulin levels), making it more **affordable and widely available** than specialized fibrosis markers such as transient elastography or liver biopsy.
2. **Reflects Both Liver Function and Inflammation**
   - Unlike ALT and AST, which primarily indicate hepatocyte injury, AGR provides insights into **both liver function (albumin production) and systemic inflammation (globulin levels)**, which are crucial in NAFLD progression (Kim et al., 2021).
3. **Potential for Early Detection of Disease Progression**
   - Low AGR values correlate with **higher inflammation and liver fibrosis**, making it a potential screening tool for high-risk NAFLD patients in diabetes (Xu et al., 2021).
4. **Non-Invasive Alternative to Liver Biopsy**
   - While liver biopsy remains the gold standard for assessing NAFLD severity, AGR offers a **less invasive and more practical alternative** for monitoring disease progression (Zhao et al., 2021).

Limitations of AGR

1. **Lack of Specificity for NAFLD**
   - AGR can be influenced by **chronic infections, autoimmune diseases, kidney dysfunction, and nutritional deficiencies**, making it less specific for liver disease alone (Liu et al., 2021).
2. **No Standardized Cutoff for NAFLD Diagnosis**
   - Unlike established fibrosis scores (e.g., FIB-4, NFS), **there is no universally accepted cutoff** for AGR in diagnosing NAFLD, requiring further validation through large-scale studies (Wang et al., 2022).
3. **Limited Use in Advanced Liver Disease**
   - AGR may lose accuracy in **cirrhotic patients**, as albumin synthesis becomes severely impaired, leading to consistently low AGR values (Huang et al., 2022).
4. **Best Used in Combination with Other Markers**
   - Given its limitations, **AGR should be used alongside other non-invasive markers** such as ALT, AST, and fibrosis scores rather than as a standalone test (Xu et al., 2021).

5. Conclusion

This review highlights the potential role of the albumin-globulin ratio (AGR) in assessing liver health in patients with Type 2 Diabetes Mellitus (T2DM) and Non-Alcoholic Fatty Liver Disease (NAFLD). AGR, a simple and cost-effective blood biomarker, reflects both hepatic function (via albumin levels) and systemic inflammation (via globulin levels). Several studies have demonstrated that a low AGR is associated with greater NAFLD severity, advanced fibrosis, and higher cardiovascular risk.

Why AGR Might Be Useful in Diagnosing NAFLD in Diabetes

Given the increasing prevalence of NAFLD in diabetic populations, early detection is crucial for preventing disease progression to cirrhosis and liver failure. AGR offers a non-invasive, readily available, and cost-effective option for identifying high-risk patients. When used in combination with traditional liver tests (ALT, AST) and fibrosis scores (FIB-4, NFS), AGR may enhance the accuracy of NAFLD diagnosis and risk stratification.

Need for More Research Before AGR Becomes a Standard Test

Despite its potential, several challenges remain before AGR can be widely implemented as a routine clinical tool:

- **Standardized cutoff values:** Large-scale studies are needed to determine optimal AGR thresholds for diagnosing and staging NAFLD.
- **Validation across diverse populations:** More research is required to assess how AGR performs in different ethnic groups, age ranges, and comorbid conditions.
- **Integration with other diagnostic models:** AGR should be evaluated in multi-marker algorithms that combine metabolic, inflammatory, and genetic risk factors for a more comprehensive assessment.

Final Thoughts

While AGR shows promise as a non-invasive biomarker for NAFLD in diabetic patients, its clinical application remains in the research stage. Future studies should focus on validating its diagnostic accuracy, optimizing its use in clinical settings, and integrating it with existing liver disease assessment tools. If proven effective, AGR could serve as a simple and widely accessible tool for improving early detection and management of NAFLD in diabetes.

References

1. Byrne, C. D., Targher, G. (2018). NAFLD: A multisystem disease. *Journal of Hepatology, 68*(2), 224-238. https://doi.org/10.1016/j.jhep.2017.11.013
2. Cusi, K. (2021). A diabetes specialist's guide to NAFLD: Diagnosis, risk factors, and treatment. *Journal of Clinical Endocrinology & Metabolism, 106*(1), 35-48. https://doi.org/10.1210/clinem/dgaa807

3. Eslam, M., Newsome, P. N., Sarin, S. K., et al. (2020). A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. *Journal of Hepatology, 73*(1), 202-209. https://doi.org/10.1016/j.jhep.2020.03.039
4. Huang, C. Y., Wang, X. H., Li, J. P., et al. (2022). Low albumin-globulin ratio is associated with advanced liver fibrosis in NAFLD patients: A cross-sectional study. *Liver International, 42*(3), 674-683. https://doi.org/10.1111/liv.15104
5. Kim, S. H., Lee, J. H., Park, S. Y., et al. (2021). Serum albumin levels and long-term outcomes in NAFLD: A population-based study. *Hepatology Communications, 5*(6), 987-999. https://doi.org/10.1002/hep4.1699
6. Liu, Y., Zheng, X., Han, Y., et al. (2021). The predictive value of AGR for liver fibrosis progression in NAFLD: A prospective cohort study. *Journal of Hepatology, 75*(5), 1075-1083. https://doi.org/10.1016/j.jhep.2021.04.012
7. Mantovani, A., Petracca, G., Beatrice, G., et al. (2020). Nonalcoholic fatty liver disease and risk of heart failure with preserved ejection fraction. *Journal of the American College of Cardiology, 75*(8), 847-857. https://doi.org/10.1016/j.jacc.2019.11.057
8. Tilg, H., Moschen, A. R., Roden, M. (2021). NAFLD and diabetes mellitus. *Nature Reviews Gastroenterology & Hepatology, 18*(5), 293-302. https://doi.org/10.1038/s41575-020-00381-6
9. Wang, Y., Li, Q., Zhang, X., et al. (2022). Prognostic value of albumin-globulin ratio in patients with liver fibrosis and NAFLD. *BMC Gastroenterology, 22*(1), 320. https://doi.org/10.1186/s12876-022-02516-3
10. Xu, L., Chen, H., Zhao, W., et al. (2021). Combining AGR with transient elastography improves non-invasive diagnosis of NAFLD fibrosis. *Liver Research, 10*(3), 237-245.
11. Younossi, Z. M., Golabi, P., de Avila, L., et al. (2019). Global epidemiology of NAFLD-related liver disease and prognosis. *Hepatology, 69*(1), 267-277. https://doi.org/10.1002/hep.30257
12. Zhao, L., Wang, M., Zheng, X., et al. (2021). The role of albumin-globulin ratio in predicting metabolic dysfunction-associated fatty liver disease. *Liver International, 41*(6), 1378-1386.
13. Zhao, L., Wang, M., Zheng, X., et al. (2021). The role of albumin-globulin ratio in predicting metabolic dysfunction-associated fatty liver disease. *Liver International, 41*(6), 1378-1386.